NCT06208007 Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
| NCT ID | NCT06208007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Goettingen |
| Condition | Heart Failure With Preserved Ejection Fraction |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-02-23 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-02-23 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
Eligibility Criteria
Inclusion Criteria: One or more of the following criteria: * Age \> 60 years * Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs) * Diabetes mellitus Type I or II * Atrial fibrillation * Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g) * BMI ≥ 30 kg/m2 * NYHA ≥ II * E/e' \> 8 Exclusion Criteria: * Left ventricular ejection fraction \< 50 % * Significant valve disease (Grade III or higher) * History of interventional or surgical valve repair * Regional wall motion abnormalities * Respiratory diseases as a known cause for dyspnea * Atrial flutter or fibrillation during examination * Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy * History of heart transplantation
Frequently Asked Questions
Who can join the NCT06208007 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure With Preserved Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06208007 currently recruiting?
Yes, NCT06208007 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Medical Center Goettingen to inquire about joining.
Where is the NCT06208007 trial being conducted?
This trial is being conducted at Göttingen, Germany.
Who is sponsoring the NCT06208007 clinical trial?
NCT06208007 is sponsored by University Medical Center Goettingen. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.